Novel Modalities,
Transformative Outcomes
Transformative Outcomes
Novel Second Generation "2+1" TCE Platform with Steric Hindrance-masking
Technology
Enabling the Creation of TCEs with Enhanced Therapeutic Effect and Safety
Jay Mei, M.D., Ph.D.
Founder, Chairman,
and Chief Executive Officer
Donald Lung, JD, MBA
Executive Director, Co-President,
and Chief Financial Officer
Bing Hou, Ph.D.
Executive Director, Co-President,
and Chief Scientific Officer
245 Main Street
Cambridge, MA 02142
